Cover Image
市場調查報告書

ExSAR Corporation:產品平台分析

ExSAR Corporation - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 294005
出版日期 內容資訊 英文 23 Pages
訂單完成後即時交付
價格
Back to Top
ExSAR Corporation:產品平台分析 ExSAR Corporation - Product Pipeline Review - 2014
出版日期: 2014年11月24日 內容資訊: 英文 23 Pages
簡介

ExSAR Corporation 是開發、提供小分子治療藥的製藥公司。該公司提供氣喘性支氣管炎等之類的上呼吸道的急性及慢性治療上使用,其他也提供高雪氏病、 肌肉萎縮性側索硬化症、帕金森氏症、貯積症、蛋白質錯誤折疊領域的治療藥。

本報告提供ExSAR Corporation 的治療藥開發平台的現狀及最新更新的各開發階段比較分析、企業和研究機關最新的新聞和發表、正在開發的治療藥、治療藥的評估、後期階段及中止的計劃相關資訊等。

ExSAR Corporation的基本資料

  • ExSAR Corporation概要
  • 主要資訊
  • 企業資料

ExSAR Corporation:R&D概要

  • 主要的治療範圍

ExSAR Corporation:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

ExSAR Corporation:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 藥物研發中的產品/聯合治療模式

ExSAR Corporation:藥物簡介

  • pyrimethamine
  • ambroxol
  • EXR-303

ExSAR Corporation:開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

ExSAR Corporation:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06538CDB

Summary

Global Markets Direct's, 'ExSAR Corporation - Product Pipeline Review - 2014', provides an overview of the ExSAR Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ExSAR Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of ExSAR Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of ExSAR Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the ExSAR Corporation's pipeline products

Reasons to buy

  • Evaluate ExSAR Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of ExSAR Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the ExSAR Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of ExSAR Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of ExSAR Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of ExSAR Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • ExSAR Corporation Snapshot
    • ExSAR Corporation Overview
    • Key Information
    • Key Facts
  • ExSAR Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • ExSAR Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • ExSAR Corporation - Pipeline Products Glance
    • ExSAR Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • ExSAR Corporation - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • ExSAR Corporation - Drug Profiles
    • pyrimethamine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ambroxol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EXR-303
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • ExSAR Corporation - Pipeline Analysis
    • ExSAR Corporation - Pipeline Products by Target
    • ExSAR Corporation - Pipeline Products by Route of Administration
    • ExSAR Corporation - Pipeline Products by Molecule Type
    • ExSAR Corporation - Pipeline Products by Mechanism of Action
  • ExSAR Corporation - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • ExSAR Corporation, Key Information
  • ExSAR Corporation, Key Facts
  • ExSAR Corporation - Pipeline by Indication, 2014
  • ExSAR Corporation - Pipeline by Stage of Development, 2014
  • ExSAR Corporation - Monotherapy Products in Pipeline, 2014
  • ExSAR Corporation - Phase II, 2014
  • ExSAR Corporation - Phase I, 2014
  • ExSAR Corporation - Discovery, 2014
  • ExSAR Corporation - Pipeline Products by Target, 2014
  • ExSAR Corporation - Pipeline by Route of Administration, 2014
  • ExSAR Corporation - Pipeline by Molecule Type, 2014
  • ExSAR Corporation - Pipeline Products by Mechanism of Action, 2014

List of Figures

  • ExSAR Corporation - Pipeline by Top 10 Indication, 2014
  • ExSAR Corporation - Pipeline by Stage of Development, 2014
  • ExSAR Corporation - Monotherapy Products in Pipeline, 2014
  • ExSAR Corporation - Pipeline Products by Top 10 Target, 2014
  • ExSAR Corporation - Pipeline by Top 10 Route of Administration, 2014
  • ExSAR Corporation - Pipeline by Top 10 Molecule Type, 2014
  • ExSAR Corporation - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top